The Journal of Pediatrics
Volume 155, Issue 3 , Pages 308-309 , September 2009

Pramlintide in Pediatric Type 1 Diabetes

  • Ilene Fennoy, MD, MPH

      Affiliations

    • Corresponding Author InformationReprint requests: Ilene Fennoy, MD, MPH, Department of Pediatrics, Columbia University, 630 W. 168th St, PH5E-522, New York, NY 10032.

References 

  1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  2. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804–812
  3. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554–1558
  4. Jakisch BI, Wagner VM, Heidtmann B, et al. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years. Diabetes Med. 2008;25:80–85
  5. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–1476
  6. Ludvik B, Kautzky-Willer A, Prager R, Thomaseth K, Pacini G. Amylin: history and overview. Diabetes Med. 1997;14(Suppl 2):S9–S13
  7. Heptulla RA, Rodriguez LM, Bomgaars L, Haymond MW. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes. 2005;54:1100–1107
  8. Hartter E, Svoboda T, Ludvik B, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34:52–54
  9. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995;38:642–648
  10. Clementi G, Caruso A, Cutuli VM, de BE, Prato A, Mico-Roxas M. Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia. 1996;52:677–679
  11. Gedulin BR, Jodka CM, Herrmann K, Young AA. Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regulatory Peptides. 2006;137:121–127
  12. Young A. Inhibition of Glucagon Secretion. In:  Andrew Y editors. Amylin: physiology and pharmacology. New York: Academic Press; 2005;p. 151–171
  13. Young AA. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes. 1997;4:282–290
  14. Buse JB, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabet. 2002;20:137–144
  15. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008;4:355–362
  16. Thompson RG, Pearson L, Kolterman OG. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia. 1997;40:1278–1285
  17. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25:724–730
  18. Rodriguez LM, Mason KJ, Haymond MW, Heptulla RA. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes. Pediatr Res. 2007;62:746–749
  19. Chase P, Lutz K, Pencek R, Zhang B, Porter L. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study. J Pediatr. 2009;155:369–373

PII: S0022-3476(09)00471-5

doi: 10.1016/j.jpeds.2009.04.065

The Journal of Pediatrics
Volume 155, Issue 3 , Pages 308-309 , September 2009

Article Tools